Protagonist Therapeutics (PTGX) Peer Comparison

$140.24

$0.87 (0.62%)

As on 03-Nov-2026 16:29EST

Market cap

$9,373 Mln

Revenue (TTM)

$282 Mln

P/E Ratio

140.6

P/B Ratio

11.1

Div. Yield

0 %

Edit

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	9,373	16,534	16,932	14,858	9,943
Revenue ($ Mln)	282	1,054	2,497	1,664	1,284
Net Profit ($ Mln)	82.91	755.85	885.14	413.60	-325.10
Net Margin (%)	29.40	71.69	35.45	24.86	-25.32
RoE (%)	11.39	--	46.96	430.03	-57.72
Price to Earnings	140.63	19.25	20.78	38.28	--
Price-To-Book	11.14	10.32	9.23	103.48	19.04

Income Statement ($ Mln)

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	281.99	1,054.37	2,496.86	1,663.74	1,283.94
Cost of Revenue	0.78	103.47	93.32	292.42	109.42
Gross Profit	44.79	588.53	2,236.43	1,167.84	902.26
Operating Expenses	223.24	841.45	1,400.14	440.53	1,497.13
Operating Profit (EBIT)	58.34	109.45	1,003.39	930.79	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	84.34	101.11	1,065.84	583.34	-325.10
Provision for Tax	1.43	-654.74	180.70	169.74	0.00
Profit after Tax (Net Income)	82.91	755.85	885.14	413.60	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	841.54	1,435.90	1,833.83	143.54	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	6.82	384.48	267.78	2,089.43	346.72
Current Liabilities	37.18	464.70	411.88	344.44	374.20
Total Liabilities	669.89	1,302.02	2,844.42	2,525.32	1,259.59

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	78.40	895.24	1,191.87	1,644.38	45.47
Current Assets	807.15	1,389.84	1,321.62	933.02	1,199.18
Total Assets	669.89	1,302.02	2,844.42	2,525.32	1,259.59
Total Debt*	9.22	449.89	162.20	2,146.65	347.75
Net Current Assets	769.97	925.52	909.75	588.59	824.98

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	57.67	51.77	884.27	651.56	-189.55
Cash Flow from Investing Activities	-49.33	-8.15	350.44	-545.81	32.32
Cash from Financing Activities	22.86	34.89	-969.59	-85.17	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-19.85	-30.01	32.82	15.61	-31.49
ROE (%)	11.39	163.18	46.96	430.03	-57.72
ROA (%)	9.89	31.68	28.91	16.19	-22.97
EBIT Margin (%)	29.91	5.73	42.02	36.28	-22.87
Net Margin (%)	29.40	71.69	35.45	24.86	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	34.81	114.85	9.12	41.15	149.04
EBIT Growth (%)	56.82	136.39	23.13	-14.99	-9.48
Net Profit Growth (%)	59.32	378.76	30.57	-25.78	-15.32
EPS Growth (%)	44.83	353.27	38.78	-23.48	-0.64
Book Value Growth (%)	12.68	816.12	-7.57	-55.81	-42.66

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-42.66	-59.76	15.79	24.99	-45.32
Price / Book Value	9.03	-80.42	5.72	162.23	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-39.02	-121.54	12.44	17.31	-47.02
Market Cap ($ Cr)	--	--	--	--	--

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.27	0.00	13.50	0.65
Short term debt to equity ratio	0.00	0.05	0.00	1.46	0.00
Current Ratio	21.71	2.99	3.21	2.71	3.20
Quick Ratio	21.71	2.32	3.14	2.31	2.94
Interest Coverage	--	1.62	--	29.73	-9.32

	Protagonist Therapeutics (PTGX)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	4.76	21.25	13.16	27.40	14.98
Asset Turnover	0.34	0.44	0.82	0.65	0.91
Receivable days	686.53	85.52	43.48	98.04	35.88
Inventory Days	--	1,056.70	96.17	254.12	354.23
Payable days	1,036.71	331.01	147.97	24.86	300.79
Cash Conversion Cycle	--	811.21	-8.32	327.29	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.